In patients with HER2-positive breast cancer, Janiszewska et al. [75] discovered a dramatic increase in a minor resistant population of PIK3CA mutant cells, and a slight decrease in the dominant population of HER2-amplified cells post neoadjuvant therapy with trastuzamab. This evidence concerns the gene ERBB2 and breast carcinoma.